Summit Therapeutics Inc. cash flow to debt ratio of -1.55K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Summit Therapeutics Inc.'s free cash flow has decreased 111.28% from $-113.67M last year to $-240.15M, signaling decreasing performance

Summit Therapeutics Inc.'s debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Summit Therapeutics Inc.'s debt has increased relative to shareholder equity from 0.02 last year to 0.04 today, signaling weakened financials

Summit Therapeutics Inc. has negative EBITDA, making leverage ratio unreliable

Summit Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Summit Therapeutics Inc. has insufficient data to evaluate this check.

Summit Therapeutics Inc.'s short-term assets of $534.58M exceed its short-term liabilities of $54.17M

Summit Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Summit Therapeutics Inc.'s return on equity of -340.55%, is lower than 15.00%, indicating bad performance

Summit Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Summit Therapeutics Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Summit Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Summit Therapeutics Inc. has negative free cash flow, indicating cash burn

Summit Therapeutics Inc.'s yearly earnings has decreased 510.72% since last year from $-176.77M to $-1.08G, signaling decreasing performance

Summit Therapeutics Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -248.14% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Summit Therapeutics Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Summit Therapeutics Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Summit Therapeutics Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Summit Therapeutics Inc. has insufficient data to evaluate this check.

Summit Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Summit Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Summit Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Summit Therapeutics Inc. has insufficient data to evaluate this check.

Summit Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Summit Therapeutics Inc. has a price-to-book ratio of 26.24x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Summit Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue